Goldman Sachs Group Inc. (GS)
NYSE: GS
· Real-Time Price · USD
630.35
16.81 (2.74%)
At close: Jun 16, 2025, 1:44 PM
2.74% (1D)
Bid | 630.16 |
Market Cap | 193.42B |
Revenue (ttm) | 126.24B |
Net Income (ttm) | 14.88B |
EPS (ttm) | 43.07 |
PE Ratio (ttm) | 14.64 |
Forward PE | 12.47 |
Analyst | Buy |
Ask | 630.35 |
Volume | 859,828 |
Avg. Volume (20D) | 2,644,900 |
Open | 618.50 |
Previous Close | 613.54 |
Day's Range | 618.43 - 632.20 |
52-Week Range | 437.37 - 672.19 |
Beta | 1.31 |
Analyst Forecast
According to 0 analyst ratings, the average rating for GS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+1.34%
Shares of financial companies are trading higher, ...
Unlock content with
Pro Subscription
1 month ago
+4.27%
Shares of banks and financial services stocks are higher after the US and China agreed to a temporary reduction in most tariffs on each other's goods. A reduction in tariffs could alleviate macro uncertainty in the lending and deal environment.

3 days ago · https://thefly.com
UroGen Pharma price target raised to $16 from $3 at Goldman SachsGoldman Sachs analyst Paul Choi raised the firm's price target on UroGen Pharma to $16 from $3 and keeps a Neutral rating on the shares following yesterday's approval of Zusduri. The firm cites the st...

5 days ago · https://247wallst.com
Billionaire Larry Fink Says Financial Systems Are ‘Safe and Sound’—Is He Right?Key Points Larry Fink, CEO of the largest asset manager in the world, believes the financial system is safe and sound. But given tariffs and the ballooning federal deficit, the investor who called the...